About
Products
Knolens
KnolScapes
Knolens
Knolens SLR
Knolens
KnolQuest
Knolens
Edge
Knolens
DataNexus
Platform
Solutions
KnolSights
Experience Knolens
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy
ImCheck Therapeutics announced positive interim data from its Phase I/II EVICTION study evaluating ICT01, a γ9δ2 T-cell activator, in combination with...
Copyright © 2025. All rights reserved
About
Terms of Service
Privacy Policy
Home/
KnloSights/
Clinical Trial Updates/
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy